Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human HVEM/TNFRSF14 Protein, Fc Tag, 100µg  

Recombinant human HVEM/TNFRSF14 Protein, Fc Tag, 100µg

Recombinant Human HVEM /TNFRSF14 Protein, Pro37-Val202, produced in human 293 cells (HEK293), Fc Tag (MALS verified)

Synonym
recombinant, human protein, TNFRSF14, ATAR, HVEA, HVEM, LIGHTR, TR2, CD270, herpesvirus entry mediator

More details

HVM-H5258-100

Availability: within 7 days

360,00 €

Background
Herpesvirus entry mediator (HVEM), also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily.

HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFß (lymphotoxin a) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTßR, the receptor for lymphotoxin aß heterotrimer. The role of the HVEM LIGHT /LTß receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.[1-4]

Source
Recombinant Human HVEM /TNFRSF14 Protein, Fc Tag (HVM-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 39 - Val 202 (Accession # NP_003811.2).
Predicted N-terminus: Leu 39

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 43.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM"
Battin, Leitner, Waidhofer-Söllner et al
Front Immunol (2022) 13, 956694
(2) "What is the optimal duration of home-video-EEG monitoring for patients with <1 seizure per day? A simulation study"
Vander, Stroganova, Doufish et al
Front Neurol (2022) 13, 938294
(3) "The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity"
Cheng, Weng, Jia et al
Front Pharmacol (2022) 13, 977025
Showing 1-3 of 688 papers.